Pexidartinib Hydrochloride Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 200 mg

Reference Brands: Turalio (USA/EU)

Category: Oncology Cancer Care

Pexidartinib Hydrochloride is available in Capsules and strengths such as 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Pexidartinib Hydrochloride is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Pexidartinib Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Pexidartinib Hydrochloride is an oral targeted therapy used in the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT), a rare condition that affects the joints and surrounding tissues. It is indicated for patients whose disease causes severe morbidity or functional limitations and cannot be effectively treated with surgery. Pexidartinib works as a kinase inhibitor that specifically blocks the activity of the colony-stimulating factor-1 receptor (CSF-1R), a key pathway involved in the growth and survival of tumor cells associated with TGCT.

By inhibiting CSF-1R signaling, pexidartinib helps reduce the accumulation of tumor cells and inflammatory cells within the affected tissues, which can lead to a reduction in tumor size and improvement in symptoms such as pain, swelling, and limited joint movement. The medicine is administered orally, offering a convenient treatment option for patients requiring long-term disease management.

Pexidartinib, marketed under the brand name Turalio, represents an important advancement in targeted therapy for rare tumor conditions. It provides a therapeutic option for patients who have limited treatment choices and helps improve disease control and quality of life in individuals affected by advanced or unresectable TGCT.